GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunovant Inc (NAS:IMVT) » Definitions » Net Margin %

IMVT (Immunovant) Net Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Immunovant Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Immunovant's Net Income for the three months ended in Dec. 2024 was $-111.12 Mil. Immunovant's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Immunovant's net margin for the quarter that ended in Dec. 2024 was 0.00%.

The historical rank and industry rank for Immunovant's Net Margin % or its related term are showing as below:


IMVT's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -133.185
* Ranked among companies with meaningful Net Margin % only.

Immunovant Net Margin % Historical Data

The historical data trend for Immunovant's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunovant Net Margin % Chart

Immunovant Annual Data
Trend Dec18 Mar20 Mar21 Mar22 Mar23 Mar24
Net Margin %
Get a 7-Day Free Trial - - - - -

Immunovant Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immunovant's Net Margin %

For the Biotechnology subindustry, Immunovant's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunovant's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunovant's Net Margin % distribution charts can be found below:

* The bar in red indicates where Immunovant's Net Margin % falls into.


;
;

Immunovant Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Immunovant's Net Margin for the fiscal year that ended in Mar. 2024 is calculated as

Net Margin=Net Income (A: Mar. 2024 )/Revenue (A: Mar. 2024 )
=-259.336/0
= %

Immunovant's Net Margin for the quarter that ended in Dec. 2024 is calculated as

Net Margin=Net Income (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=-111.122/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immunovant  (NAS:IMVT) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


Immunovant Net Margin % Related Terms

Thank you for viewing the detailed overview of Immunovant's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunovant Business Description

Traded in Other Exchanges
N/A
Address
320 West 37th Street, 6th Floor, New York, NY, USA, 10018
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
Executives
Andrew J. Fromkin director C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FL, CAMBRIDGE MA 02139
William L. Macias officer: Chief Medical Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Eva Renee Barnett officer: Chief Financial Officer C/O IMMUNOVANT, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Peter Salzmann director, officer: Chief Executive Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
Jay S Stout officer: Chief Technology Officer C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Atul Pande director C/O AXOVANT SCIENCES, INC., 1441 BROADWAY, 3RD FLOOR, NEW YORK NY 10018
Douglas J. Hughes director C/O EARGO, INC., 2665 NORTH FIRST STREET, SUITE 300, SAN JOSE CA 95134
Mark S. Levine officer: Chief Legal Officer 1601 TRAPELO ROAD, SUITE 284, WALTHAM MA 02451
Julia G. Butchko officer: Chief Dev. & Tech. Officer 320 W 37TH STREET, 3RD FLOOR, NEW YORK NY 10016
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Frank Torti director 2855 SAND HILL ROAD, MENLO PARK CA 94025
Rita Jain officer: Chief Medical Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Michael James Elliott officer: Chief Scientific Officer 320 WEST 37TH STREET, NEW YORK NY 10018
Eric Venker director C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018